Acompanhe as Notícias da Recifes

A subanalysis of a single-group, open-label, Phase IIb study found that olorofim, a first-in-class orotomide antifungal agent that does not have U.S. FDA approval, showed efficacy in patients with disseminated coccidioidomycosis (DCM), a rare complication of Valley Fever in which

Tiny particles made from the membranes of human immune cells could offer a promising new way to fight fungal infections that are becoming harder to treat. Engineers at the University of California San Diego created antifungal nanoparticles that target Candida albicans, a fungus r